This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZSAN Zosano Pharma (ZSAN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zosano Pharma Stock (NASDAQ:ZSAN) 30 days 90 days 365 days Advanced Chart Get Zosano Pharma alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range$0.52▼$112.0052-Week Range$0.46▼$37.45Volume5,685 shsAverage Volume425,375 shsMarket Capitalization$980.40P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. Read More Receive ZSAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZSAN Stock News HeadlinesMicroneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass TechnologiesMarch 7, 2025 | globenewswire.comAktuelle Empfehlungen zur ZOSANOJuly 28, 2024 | finanznachrichten.deTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the biggest money moves of the last 30 years – including the internet, the tech boom, and bitcoin (before it soared 8,000%). Today, he's a multimillionaire tech investor. And he says Congress just passed a radical new law that could create more millionaires in the years ahead than anything else.September 12 at 2:00 AM | Stansberry Research (Ad)HOOK HOOKIPA Pharma Inc.April 12, 2024 | seekingalpha.comEast Bay Business NewsMay 18, 2023 | bizjournals.comAstellas PharmaApril 6, 2023 | forbes.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationFebruary 5, 2023 | finance.yahoo.comZosano Pharma Corporation (ZSANQ)November 5, 2022 | ca.finance.yahoo.comSee More Headlines ZSAN Stock Analysis - Frequently Asked Questions How were Zosano Pharma's earnings last quarter? Zosano Pharma Co. (NASDAQ:ZSAN) released its earnings results on Friday, May, 13th. The biotechnology company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($1.75) by $0.01. Zosano Pharma had a negative net margin of 8,375.11% and a negative trailing twelve-month return on equity of 177.06%. When did Zosano Pharma's stock split? Zosano Pharma's stock reverse split on Tuesday, April 12th 2022.The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Zosano Pharma IPO? Zosano Pharma (ZSAN) raised $47 million in an IPO on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO. What other stocks do shareholders of Zosano Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zosano Pharma investors own include Tonix Pharmaceuticals (TNXP), NIO (NIO), Adamis Pharmaceuticals (ADMP), Bionano Genomics (BNGO), NightHawk Biosciences (NHWK), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS). Company Calendar Last Earnings5/13/2022Today9/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZSAN CIK1587221 Webwww.zosanopharma.com Phone(510) 745-1200FaxN/AEmployees40Year Founded2006Profitability EPS (Trailing Twelve Months)($14.5034) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.92 million Net Margins-8,375.11% Pretax Margin-8,375.11% Return on Equity-177.06% Return on Assets-119.14% Debt Debt-to-Equity RatioN/A Current Ratio1.61 Quick Ratio1.61 Sales & Book Value Annual Sales$790 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.74 per share Price / Book0.00Miscellaneous Outstanding Shares4,902,000Free Float4,784,000Market Cap$980.40 OptionableNot Optionable Beta3.30 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ZSAN) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zosano Pharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zosano Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZSAN Stock Alerts